Neovacs to expand TNF-alpha kinoid programme
This article was originally published in Scrip
Executive Summary
Neovacs, a French biotech spun out of the Pierre and Marie Curie University, is set to expand clinical testing of its lead immunotherapy candidate, TNF-alpha kinoid, to include rheumatoid arthritis patients following positive preliminary findings from a Phase I/II study in Crohn's disease patients.